TG Therapeutics Inc (TGTX)
Pretax margin
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -13,885 | 95,777 | 41,616 | 13,062 | -25,906 | -175,654 | -168,554 | -198,335 | -238,679 | -288,498 | -326,485 | -348,100 | -342,979 | -344,505 | -318,892 | -279,380 | -230,734 | -205,501 | -188,830 | -172,870 |
| Revenue (ttm) | US$ in thousands | 262,359 | 340,582 | 280,254 | 222,343 | 180,883 | 18,875 | 6,331 | 2,784 | 5,025 | 6,961 | 7,912 | 6,689 | 4,406 | 2,414 | 907 | 152 | 152 | 152 | 152 | 152 |
| Pretax margin | -5.29% | 28.12% | 14.85% | 5.87% | -14.32% | -930.62% | -2,662.36% | -7,124.10% | -4,749.83% | -4,144.49% | -4,126.45% | -5,204.07% | -7,784.36% | -14,271.13% | -35,158.99% | -183,802.63% | -151,798.68% | -135,198.03% | -124,230.26% | -113,730.26% |
September 30, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-13,885K ÷ $262,359K
= -5.29%
TG Therapeutics Inc's pretax margin has shown significant fluctuations over the past few quarters. The pretax margin reflects the company's ability to generate profits before accounting for taxes relative to its total revenue.
In the most recent quarter, the pretax margin was -5.29%, indicating that the company incurred a loss before taxes. This is a deterioration from the previous quarter's pretax margin of 28.12%, when the company was profitable.
Looking further back, the company's performance has been volatile, with periods of both profitability and losses. The pretax margin in previous quarters ranged from negative percentages, such as -14.32% and -930.62%, to positive percentages like 14.85% and 5.87%.
The negative pretax margins in several quarters suggest that the company may have experienced challenges in controlling its operating expenses relative to its revenue. It is important for TG Therapeutics Inc to monitor its cost structure and revenue generation to improve its profitability and maintain a sustainable pretax margin in the future.
Peer comparison
Sep 30, 2024